IIID Member Company Develops First Domestically Produced Vinorelbine

Sana Pharmed, a knowledge-based member company of the Iran International Innovation District (IIID), has announced the mass production of the first domestically developed version of Vinorelbine, a high-tech anti-cancer drug. This achievement eliminates the country’s reliance on imports for this vital medication.

Saman Pourzia, CEO and co-founder of Sana Pharmed, stated that the development of the drug, branded as Sanarelbin, took over three years. “Given the lack of production infrastructure in the country, our company established a specialized production line for this product,” he noted. This indigenized production is expected to save the country more than $5 million annually.

Pourzia confirmed that Sanarelbin is now available in specialized pharmacies and has received positive feedback from both physicians and patients, aiming to ensure equitable access and reduce treatment costs for families.

Sana Pharmed began its operations in 2019 at the Azadi Innovation Factory, a branch of the IIID, focusing on specialized drugs and advanced supplements, and has launched over eight products to date.

Looking ahead, the company plans to introduce two new high-tech drugs to the Iranian market for the first time in 2025, marking a significant step for the nation’s pharmaceutical industry. Pourzia also acknowledged the support from Pardis Technology Park (PTP) and the Hanam Pharmed accelerator, emphasizing the company’s commitment to localizing essential medicines through sustainable innovation.